Vol 6, Supplement 6 (August 29, 2017): Translational Cancer Research

Editorial

Inhibiting C5a/C5aR axis reduces myeloid-derived suppressor cells and enhances PD-1 blockade therapy in lung cancer

Sherven Sharma, Steven Dubinett

PDF Pages: S944-S948 Full Text (3410) COI Form Open Access

New incriminating evidence against IGF2

Wen Ding, Lina A. Shehadeh

PDF Pages: S949-S952 Full Text (4801) COI Form Open Access

Cancer prevention through better sleeping habits: the circadian clock and hepatocellular cancer

Katarzyna Trebska-McGowan, Trevor W. Reichman

PDF Pages: S953-S956 Full Text (3008) COI Form Open Access

From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein

Felicia L. Lenzo, William G. Cance

PDF Pages: S957-S960 Full Text (4412) Open Access

Treatment of elderly patients with glioblastoma: new lessons from CE.6

Toral R. Patel, Ankur R. Patel, Sunit Das

PDF Pages: S961-S963 Full Text (1672) COI Form Open Access

The importance of novel molecular biomarker of early stage lung adenocarcinoma

Hideki Ujiie, Kazuhiro Yasufuku

PDF Pages: S964-S968 Full Text (2567) COI Form Open Access

Synergizing genome editing and cancer immunotherapy

Richard Gabriel, Friederike Knipping, Christof von Kalle

PDF Pages: S969-S972 Full Text (3661) COI Form Open Access

Postoperative chemoradiotherapy for elderly patients with glioblastoma: worsening frailty or increasing survival?

Valentina Pinzi

PDF Pages: S973-S975 Full Text (2075) COI Form Open Access

REGATTA trial: its achievement and the issues unsolved

Seung-Young Oh, Hyuk-Joon Lee

PDF Pages: S976-S978 Full Text (3694) COI Form Open Access

Signatures of field cancerization: a step towards earlier detection of esophageal adenocarcinoma

Aaron D. DeWard, Rebecca J. Critchley-Thorne

PDF Pages: S979-S981 Full Text (3948) COI Form Open Access

Tumor metabolism and prognostic role of EZH2 in non-small cell lung cancer

Egesta Lopci, Sabrina Rossi

PDF Pages: S982-S988 Full Text (2860) COI Form Open Access

Radiotherapy benefits outweigh risks for breast cancer in modern era

Chih-Jen Huang, Hsin-Hua Lee

PDF Pages: S989-S992 Full Text (2723) COI Form Open Access

A role for lnc-DILC in liver cancer stem cells

Tengfei Zhou, Fang Wang

PDF Pages: S993-S994 Full Text (1905) COI Form Open Access

BRCA1 and BRCA2: two genes, multiple clinical applications

Ekatherina Sh. Kuligina, Evgeny N. Imyanitov

PDF Pages: S995-S998 Full Text (2430) COI Form Open Access

Vesicular control of metastasis: entrap the “virtuous” and free the “wicked” microRNA

Fahd Al-Mulla

PDF Pages: S999-S1002 Full Text (2163) COI Form Open Access

CAR-T cell in vivo tracking method using PET scan with the reporter gene and new investigational tracer [¹⁸F] FHBG

Tsubasa Miyazaki, Hitoshi Aiyama, Eiichi Ishikawa

PDF Pages: S1003-S1005 Full Text (6236) COI Form Open Access

Post-operative seizure prophylaxis in gliomas

Andrew Neal, Patrick Kwan, Andrew Morokoff, Terence John O’Brien

PDF Pages: S1006-S1009 Full Text (4721) COI Form Open Access

Should alectinib or ceritinib be given as first line therapy for ALK positive non-small cell lung cancer patients instead of crizotinib?

Godefridus J. Peters, Ittai B. Muller, Elisa Giovannetti

PDF Pages: S1010-S1013 Full Text (6227) COI Form Open Access

Effective combinatorial immunotherapy for castration-resistant prostate cancer: new future chance?

Pina Ziranu, Francesco Atzori, Marco Puzzoni, Laura Demurtas, Giorgio Astara, Mario Scartozzi

PDF Pages: S1014-S1017 Full Text (2516) COI Form Open Access

The need for speed: how PD1-blockade only works if T cells are properly activated

Johannes vom Berg, Sebastian Kobold

PDF Pages: S1018-S1021 Full Text (7391) Open Access

Elderly patients with glioblastoma: where are we going?

Giuseppe Lombardi, Ardi Pambuku, Vittorina Zagonel

PDF Pages: S1022-S1024 Full Text (2220) COI Form Open Access

Would the skyrocketed advances of immune checkpoint inhibitors over chemotherapy be stumbled by the safety issues?

Kyrillus S. Shohdy, Omar Abdel-Rahman

PDF Pages: S1025-S1026 Full Text (1470) COI Form Open Access

The “eyes” have it?—intra- and inter-observer reproducibility of the PD-L1 companion diagnostic assay

Steven G. Gray, Mark C. Wright, Stephen P. Finn

PDF Pages: S1027-S1029 Full Text (1990) COI Form Open Access

Prophylactic cranial irradiation for extensive-stage small-cell lung cancer: an evolving view

Ethan B. Ludmir, Steven H. Lin

PDF Pages: S1030-S1034 Full Text (2167) COI Form Open Access

Unraveling the hurdles in the development of HER2-targeted agents for metastatic gastro-esophageal cancer patients

Cinta Hierro, Maria Alsina, Josep Tabernero

PDF Pages: S1035-S1039 Full Text (2551) Open Access

Exosome mediated phenotypic changes in lung cancer pathophysiology

Yoshihisa Shimada, John D. Minna

PDF Pages: S1040-S1042 Full Text (4648) COI Form Open Access

Intensity modulated radiotherapy for head-and-neck cancer: discussing safety of modern radiation techniques

Julie van der Veen, Sandra Nuyts

PDF Pages: S1043-S1048 Full Text (7066) COI Form Open Access

Perspective on long noncoding RNA functionality

Agnik Haldar, Sanga Mitra, Jayprokas Chakrabarti

PDF Pages: S1049-S1053 Full Text (2859) COI Form Open Access

Tenascin-C a novel regulator of brain tumor-initiating cells (BTIC) in glioma acts through NOTCH

Juliano Andreoli Miyake, Marc Vooijs

PDF Pages: S1054-S1056 Full Text (3387) COI Form Open Access

Tenascin-C induces expression of the Notch ligand Jagged1 to promote glioma growth

Elena Parmigiani, Verdon Taylor, Claudio Giachino

PDF Pages: S1057-S1060 Full Text (2931) COI Form Open Access

Avelumab: a promising PD-L1 inhibitor for lung cancer (with inconvenient infusional reactions)

Tawee Tanvetyanon

PDF Pages: S1061-S1063 Full Text (2943) COI Form Open Access

Back into focus: tumour-associated macrophages and their role in immune checkpoint inhibition

Sebastian Marwitz, Torsten Goldmann

PDF Pages: S1064-S1065 Full Text (1846) COI Form Open Access

Lymph node metastasis in oesophageal cancer—what we (do not) know?

Janusz Włodarczyk, Jarosław Kużdżał

PDF Pages: S1066-S1068 Full Text (5838) COI Form Open Access

Brigatinib entering the clinic for ALK rearranged metastatic NSCLC: editorial on a randomized multicenter phase II study with two brigatinib dose regimens

Adrianus J. de Langen

PDF Pages: S1069-S1073 Full Text (2574) Open Access

Ceritinib in ROS1-positive non-small cell lung cancer patients: does clinical evidence carry clinical impact?

Francesco Facchinetti, Marcello Tiseo

PDF Pages: S1074-S1079 Full Text (5023) COI Form Open Access

Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28

Leonardo Chicaybam, Prasad S. Adusumilli

PDF Pages: S1080-S1083 Full Text (4703) COI Form Open Access

Unraveling bio-social hierarchy in cancer collective invasion: symbiosis between leaders and followers

Fransisca Leonard, Biana Godin

PDF Pages: S1084-S1087 Full Text (3697) COI Form Open Access

Deferoxamine may enhance 5-aminolevulinic acid-based fluorescence in glioma surgery

Hirohito Yano, Jun Shinoda, Toru Iwama

PDF Pages: S1088-S1090 Full Text (2386) Open Access

Tumor microenvironments of NSCLC are more heterogeneous than you would think—supported by image analysis-based assessment of PD-L1 and tumor-associated immune cell densities

Mari Mino-Kenudson

PDF Pages: S1091-S1097 Full Text (2057) COI Form Open Access

Diffuse intrinsic pontine gliomas: the future of combination therapy with mTORC1/2 inhibitors and radiation

Idoia Garcia, Juncal Aldareguia, Ander Matheu

PDF Pages: S1098-S1100 Full Text (2151) COI Form Open Access

Macrophages/microglia in glioblastoma: a Zelig-like story of changing phenotypes

Lucia Lisi, Grazia Graziani, Pierluigi Navarra

PDF Pages: S1101-S1103 Full Text (2386) COI Form Open Access

Epigenetic profiling of tumor infiltrating lymphocytes

Jill E. Slansky, Laura D. Harmacek, Brian P. O’Connor

PDF Pages: S1104-S1107 Full Text (2647) COI Form Open Access

Perspective

Progress and impact of clinical phosphoproteomics on precision oncology

Nadia Lima, Alex T. J. Lee, Paul H. Huang

PDF Pages: S1108-S1114 Full Text (3876) COI Form Open Access

Letter to the Editor

What is the significance of TP53 and KRAS mutation for immunotherapy in non-small cell lung cancer?

Zhong-Yi Dong, Yi-Long Wu

PDF Pages: S1115-S1117 Full Text (4717) COI Form Open Access

Detection of clinically relevant T-cell receptors requires tailored approaches, and TCR gene therapy carries inherent risks

Lorenz Jahn, Mirjam H. M. Heemskerk

PDF Pages: S1118-S1120 Full Text (2678) COI Form Open Access

Disclosure:

This supplement was published without any sponsorship or funding.